top of page
News, Events and Updates
Search
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX® 3-71 in Humans
Jan 24, 2024
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Jan 16, 2024
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Nov 24, 2023
Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of
Oct 25, 2023
Anavex Life Sciences Reports Publication of ANAVEX®3-71
Aug 7, 2023
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 20, 2023
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
May 2, 2023
Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Nov 28, 2022
Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022
Aug 2, 2022
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Jun 21, 2022
Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71
Jan 10, 2022
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
